<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222816</url>
  </required_header>
  <id_info>
    <org_study_id>IEC/AIIMS BBSR/PG Th/19-20/76</org_study_id>
    <nct_id>NCT04222816</nct_id>
  </id_info>
  <brief_title>Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder</brief_title>
  <official_title>Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bipolar affective disorder or manic -depressive psychosis (MDP) is a mood disorder affecting
      2.4% of the global population . Lithium is considered as the &quot;gold standard&quot; for the
      treatment of bipolar disorder but the clinical use of lithium is often restricted due to its
      narrow therapeutic range and adverse effects.

      In a published case report, Bleiwiss H found that sodium chloride supplementation diminished
      the adverse effects caused by lithium The literature search also revealed that till date,
      there is no published clinical study evaluating the effect of dietary intake of sodium in
      preventing the fluctuations of serum lithium level and lithium toxicity Therefore, a
      randomized clinical trial has been designed to evaluate the effect of regulated add -on
      dietary sodium chloride on serum lithium levels in bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar affective disorder or manic -depressive psychosis (MDP) is a mood disorder affecting
      2.4% of the global population. Lithium is considered as the &quot;gold standard&quot; for the treatment
      of bipolar disorder but the clinical use of lithium is often restricted due to its narrow
      therapeutic range and adverse effects.One of the major adverse effects of lithium is
      nephrogenic diabetes insipidus which is due to long -term renal dysfunction.

      In the initial months of lithium therapy, psychiatrists face difficulty in titrating the dose
      and stabilizing serum lithium level and this fluctuation of serum lithium level may be due to
      a lithium-induced sodium depleted state.

      In a published case report, Bleiwiss H found that sodium chloride supplementation diminished
      the adverse effects caused by lithium. 8 In another case report, Tomita et al demonstrated
      that the change in sodium chloride intake can bring about changes in serum lithium and help
      in stabilizing the levels of serum lithium concentration.

      As all the case reports are from abroad, the effect of dietary sodium on serum lithium level
      among Indian population is completely unknown. The literature search also revealed that till
      date, there is no published clinical study evaluating the effect of dietary intake of sodium
      in preventing the fluctuations of serum lithium level and lithium toxicity. Therefore, a
      randomized clinical trial has been designed to evaluate the effect of regulated add -on
      dietary sodium chloride on serum lithium levels in bipolar disorder. This study may help to
      explore the role of add -on sodium chloride in decreasing the fluctuations in the serum
      lithium level and improving the clinical outcome of patients with bipolar disorders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open label, parallel group, active controlled clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percentage of bipolar patients showing fluctuation in serum lithium level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum lithium level will be done by electrolyte analyzer. The patients showing fluctuations ( fluctuation is defined as serum lithium &lt;0.6 mEq/ L or &gt;0.8 mEq/ L in maintenance phase) in serum lithium level between the groups over 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum sodium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Will be done by electrolyte analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Will be done by electrolyte analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Will be done by autoanalyser.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aldosterone</measure>
    <time_frame>12 weeks</time_frame>
    <description>Will be done by commercially available ELISA kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG changes</measure>
    <time_frame>12 weeks</time_frame>
    <description>ECG changes for lithium toxicity (T wave inversion, PR prolongation, QT prolongation), hyponatremia (P wave alterations), hypernatremia (short PR interval and diffuse ST depression) will be looked for</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lithium</measure>
    <time_frame>12 weeks</time_frame>
    <description>Will be done by electrolyte analyzer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Bipolar Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Lithium carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lithium carbonate is prescribed 800-900 mg per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Add-on Sodium chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium chloride 1gm per day per will be prescribed along with Lithium carbonate 800-900 mg per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>Lithium carbonate 800-900 mg orally daily for 12 weeks</description>
    <arm_group_label>Add-on Sodium chloride</arm_group_label>
    <arm_group_label>Lithium carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>Sodium chloride 1gm daily per orally for 12 weeks</description>
    <arm_group_label>Add-on Sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 -60 years, of either sex with the clinical diagnosis of bipolar
             disorder (DSM V) who are on maintenance lithium therapy for ≥ 1month and ≤ 6 months.

          -  Patients with normal serum sodium level (135 -145 mEq/L) and serum lithium in the
             optimum therapeutic range (&lt;0.6 mEq/ L or &gt;0.8 mEq/ L) .

        Exclusion Criteria:

          -  Patients with comorbidities like other psychiatric disorder s, organicity, substance
             abuse, personality disorder, intellectual disability and other neurotic disorders .

          -  Patients with any renal, cardiovascular, neurologica l, endocrinal and hepatic
             dysfunction.

          -  Patients suffering from diarrhoea, dehydration

          -  History of any invasive neurosurgical/ non -invasive neuropsychiatric procedure.

          -  Medication history of psychoactive or central nervous system depressant drugs.

          -  Patients who are on NSAIDs, ACE inhibitors, antiarrhythmics, diuretics and
             neuromuscular blocking agents .

          -  Pregnant and nursing women .

          -  Patients with drug/alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DEBASISH HOTA, DM</last_name>
    <role>Study Director</role>
    <affiliation>PROFESSOR AND HEAD OF THE DEPARTMENT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RITUPARNA MAITI, MD</last_name>
    <phone>9438884191</phone>
    <email>pharm_rituparna@aiimsbhubaneswar.edu.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BISWA R MISHRA, MD</last_name>
    <phone>9438884220</phone>
    <email>brm1678@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aiims Bhubaneswar</name>
      <address>
        <city>Khorda</city>
        <state>Orissa</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RITUPARNA MAITI, MD</last_name>
      <phone>9438884191</phone>
      <email>pharm_rituparna@aiimsbhubaneswar.edu.in</email>
    </contact>
    <contact_backup>
      <last_name>BISWA RANJAN MISHRA, MD</last_name>
      <phone>9438884220</phone>
      <email>brm1678@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M, Medina-Mora ME, Ono Y, Posada-Villa J, Sagar R, Wells JE, Zarkov Z. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 Mar;68(3):241-51. doi: 10.1001/archgenpsychiatry.2011.12.</citation>
    <PMID>21383262</PMID>
  </reference>
  <reference>
    <citation>Bleiweiss H. Salts supplements with lithium. Lancet. 1970 Feb 21;1(7643):416.</citation>
    <PMID>4189720</PMID>
  </reference>
  <reference>
    <citation>Tomita T, Goto H, Sumiya K, Yoshida T, Tanaka K, Kohda Y. Stabilization of the Serum Lithium Concentration by Regulation of Sodium Chloride Intake: Case Report. Yakugaku Zasshi. 2016;136(3):517-21. doi: 10.1248/yakushi.15-00256.</citation>
    <PMID>26935095</PMID>
  </reference>
  <reference>
    <citation>Demers RG, Heninger GR. Sodium intake and lithium treatment in mania. Am J Psychiatry. 1971 Jul;128(1):100-4.</citation>
    <PMID>4949647</PMID>
  </reference>
  <reference>
    <citation>Selvarajan S, Manohar H, Das S, Sakkarabani P, Kandasamy P. Lithium prophylaxis in early-onset Bipolar disorder: a descriptive study. Asian J Psychiatr. 2019 Aug;44:172-174. doi: 10.1016/j.ajp.2019.07.053. Epub 2019 Jul 30.</citation>
    <PMID>31394485</PMID>
  </reference>
  <reference>
    <citation>Tondo L, Vázquez GH, Baldessarini RJ. Depression and Mania in Bipolar Disorder. Curr Neuropharmacol. 2017 Apr;15(3):353-358. doi: 10.2174/1570159X14666160606210811. Review.</citation>
    <PMID>28503106</PMID>
  </reference>
  <reference>
    <citation>Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, Stein DJ, Zaslavsky AM, Aguilar-Gaxiola S, Alonso J, Andrade L, Benjet C, de Girolamo G, de Graaf R, Demyttenaere K, Fayyad J, Haro JM, Hu Cy, Karam A, Lee S, Lepine JP, Matchsinger H, Mihaescu-Pintia C, Posada-Villa J, Sagar R, Ustün TB. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry. 2011 Jan;68(1):90-100. doi: 10.1001/archgenpsychiatry.2010.180.</citation>
    <PMID>21199968</PMID>
  </reference>
  <reference>
    <citation>Murthy RS. National Mental Health Survey of India 2015-2016. Indian J Psychiatry. 2017 Jan-Mar;59(1):21-26. doi: 10.4103/psychiatry.IndianJPsychiatry_102_17.</citation>
    <PMID>28529357</PMID>
  </reference>
  <reference>
    <citation>Mandal S, Mamidipalli SS, Mukherjee B, Hara SKH. Perspectives, attitude, and practice of lithium prescription among psychiatrists in India. Indian J Psychiatry. 2019 Sep-Oct;61(5):451-456. doi: 10.4103/psychiatry.IndianJPsychiatry_451_18.</citation>
    <PMID>31579157</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>RITUPARNA MAITI</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar affective disorder</keyword>
  <keyword>Lithium</keyword>
  <keyword>Manic depressive psychosis</keyword>
  <keyword>Sodium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

